Molecular basis and clinical implications of opioid tolerance and opioid-induced hyperalgesia

Acute Pain Management

Volumn 9780521874915, Issue , 2009, Pages 114-144

  Chu, Larry F ^a   Clark, David ^b   Angst, Martin S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650686298     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576706.011     Document Type: Chapter

References (337)

1. Booth M. Opium: A History. New York, NY: St. Martin’s Press; 1998.
2. Krjtikos P, Papadaki, SP. The history of poppy and of opium and their expansion in antiquity. Bull Narc. 1967; 3: 17-38.
3. WHO. Achieving Balance in National Opioids Control Policy: Guidelines for Assessment. Geneva, Switzerland: World Health Organization; 2000.
4. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003; 60 (6): 927-934.
5. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology. 2002; 59 (7): 1015-1021.
6. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003; 348 (13): 1223-1232.
7. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105 (1-2): 71-78.
8. Dellemijn PL, Vanneste JA. Randomised double-blind activeplacebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet. 1997; 349 (9054): 753-758.
9. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999; 26 (4): 862-869.
10. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000; 160 (6): 853-860.
11. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996; 347 (8995): 143-147.
12. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled-release codeine in chronic nonmalignant pain: a randomized, placebo-controlled clinical trial. Pain. 1995; 62 (2): 169-178.
13. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112 (3): 372-380.
14. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005; 65 (12 suppl 4): 32-49.
15. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007; 23 (4): 287-299.
16. Meier B. Sales of painkiller grew rapidly, but success brought a high cost. New York Times. March 5, 2001.
17. Adams C. Painkiller’s sales far exceeded levels anticipated by maker. Wall Street Journal. May 16, 2002.
18. Yadgood MC, Miller PJ, Mathews PA. Relieving the agony of the new pain management standards. Am J Hosp Palliat Care. 2000; 17 (5): 333-341.
19. Lippe PM. The decade of pain control and research. Pain Med. 2000; 1 (4): 286.
20. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007; 105 (1): 205-221.
21. Cousins MJ, Brennan F, Carr DB. Pain relief: a universal human right. Pain. Nov 2004; 112 (1-2): 1-4.
22. Thomson H. A new law to improve pain management and endof-life care: learning how to treat patients in pain and near death must become a priority. West J Med. 2001; 174 (3): 161-162.
23. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U. S. primary care physicians from 1992 to 2001. J Pain. 2006; 7 (4): 225-235.
24. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002; 23 (2): 131-137.
25. Bell JR. Australian trends in opioid prescribing for chronic noncancer pain, 1986-1996. Med J Aust. 1997; 167 (1): 26-29.
26. RxList: The Internet Drug index. The Top 300 Prescriptions for 2005 by Number of US Prescriptions Dispensed. http: //www. rxlist. como/top200. htm. Accessed May 7, 2007.
27. Rowbotham MC, Lindsey CD. How effective is long-term opioid therapy for chronic noncancer pain? Clin J Pain. 2007; 23 (4): 300-302.
28. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104 (3): 570-587.
29. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep. 2006; 10 (1): 67-70.
30. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005; 80 (2-3): 319-324.
31. Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain? Neuro Report. 2003; 14 (1): 1-7.
32. Twycross RG. Choice of strong analgesic in terminal cancer: diamorphine or morphine? Pain. 1977; 3 (2): 93-104.
33. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006; 7 (1): 43-48.
34. Marsden CA. Dopamine: the rewarding years. Br J Pharmacol. 2006; 147 (suppl 1): 136-144.
35. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007; 23 (4): 307-315.
36. Stein DJ, van Honk J, Ipser J, Solms M, Panksepp J. Opioids: from physical pain to the pain of social isolation. CNS Spectr. 2007; 12 (9): 669-670, 672-674.
37. Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg. 1998; 86 (6): 1307-1311.
38. Gustorff B, Nahlik G, Hoerauf KH, Kress HG. The absence of acute tolerance during remifentanil infusion in volunteers. Anesth Analg. 2002; 94 (5): 1223-1228, table of contents.
39. Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 1999; 46 (9): 872-877.
40. Cooper DW, Lindsay SL, Ryall DM, Kokri MS, Eldabe SS, Lear GA. Does intrathecal fentanyl produce acute cross-tolerance to i. v. morphine? Br J Anaesth. 1997; 78 (3): 311-313.
41. Crawford MW, Hickey C, Zaarour C, Howard A, Naser B. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg. 2006; 102 (6): 1662-1667.
42. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000; 93 (2): 409-417.
43. Cortinez LI, Brandes V, Munoz HR, Guerrero ME, Mur M. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br J Anaesth. 2001; 87 (6): 866-869.
44. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003; 98 (6): 1415-1421.
45. Delvaux B, Ryckwaert Y, Van Boven M, De Kock M, Capdevila X. Remifentanil in the intensive care unit: tolerance and acute withdrawal syndrome after prolonged sedation. Anesthesiology. 2005; 102 (6): 1281-1282.
46. Tobias JD, Berkenbosch JW. Tolerance during sedation in a pediatric ICU patient: effects on the BIS monitor. J Clin Anesth. 2001; 13 (2): 122-124.
47. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Agedependent opioid escalation in chronic pain patients. Anesth Analg. 2005; 100 (6): 1740-1745.
48. de Leon-Casasola OA, Myers DP, Donaparthi S, et al. A comparison of postoperative epidural analgesia between patients with chronic cancer taking high doses of oral opioids versus opioidnaive patients. Anesth Analg. 1993; 76 (2): 302-307.
49. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain. 1995; 61 (2): 195-201.
50. Joels CS, Mostafa G, Matthews BD, et al. Factors affecting intravenous analgesic requirements after colectomy. J Am Coll Surg. 2003; 197 (5): 780-785.
51. Kain ZN, Sevarino F, Alexander GM, Pincus S, Mayes LC. Preoperative anxiety and postoperative pain in women undergoing hysterectomy: a repeated-measures design. J Psychosom Res. 2000; 49 (6): 417-422.
52. Kalkman CJ, Visser K, Moen J, Bonsel GJ, Grobbee DE, Moons KG. Preoperative prediction of severe postoperative pain. Pain. 2003; 105 (3): 415-423.
53. Riley TR, 3rd. Predictors of pain medication use after percutaneous liver biopsy. Dig Dis Sci. 2002; 47 (10): 2151-2153.
54. Thomas T, Robinson C, Champion D, McKell M, Pell M. Prediction and assessment of the severity of post-operative pain and of satisfaction with management. Pain. 1998; 75 (2-3): 177-185.
55. Breckenridge J, Clark JD. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. J Pain. 2003; 4 (6): 344-350.
56. Galer BS, Lee D, Ma T, Nagle B, Schlagheck TG. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain. 2005; 115 (3): 284-295.
57. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of longterm efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain. 2001; 2 (4): 197-204.
58. Bernstein MA, Welch SP. mu-Opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res. 1998; 55 (2): 237-242.
59. Ben Y, Smith AP, Schiller PW, Lee NM. Tolerance develops in spinal cord, but not in brain with chronic [Dmt1]DALDA treatment. Br J Pharmacol. 2004; 143 (8): 987-993.
60. Buzas B, Rosenberger J, Cox BM. Mu and delta opioid receptor gene expression after chronic treatment with opioid agonist. Neuro Report. 1996; 7 (9): 1505-1508.
61. Ray SB, Gupta YK, Wadhwa S. Expression of opioid receptor-like 1 (ORL1) & mu opioid receptors in the spinal cord of morphine tolerant mice. Indian J Med Res. 2005; 121 (3): 194-202.
62. Ronnekleiv OK, Bosch MA, Cunningham MJ, Wagner EJ, Grandy DK, Kelly MJ. Downregulation of mu-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment. Neurosci Lett. 1996; 216 (2): 129-132.
63. Johnson EE, Christie MJ, Connor M. The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neurosignals. 2005; 14 (6): 290-302.
64. Marie N, Aguila B, Allouche S. Tracking the opioid receptors on the way of desensitization. Cell Signal. 2006; 18 (11): 1815-1833.
65. Zuo Z. The role of opioid receptor internalization and betaarrestins in the development of opioid tolerance. Anesth Analg. 2005; 101 (3): 728-734, table of contents.
66. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem. 1995; 65 (4): 1636-1645.
67. Deng HB, Yu Y, Pak Y, et al. Role for the C-terminus in agonistinducedmu opioid receptor phosphorylation and desensitization. Biochemistry. 2000; 39 (18): 5492-5499.
68. Deng HB, Yu Y, Wang H, Guang W, Wang JB. Agonist-inducedmu opioid receptor phosphorylation and functional desensitization in rat thalamus. Brain Res. 2001; 898 (2): 204-214.
69. Zhang L, Yu Y, Mackin S, Weight FF, Uhl GR, Wang JB. Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem. 1996; 271 (19): 11449-11454.
70. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Hollt V. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. Embo J. 2004; 23 (16): 3282-3289.
71. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol. 2004; 66 (1): 106-112.
72. Bohn LM, Gainetdinov RR, Caron MG. G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. Neuromolecular Med. 2004; 5 (1): 41-50.
73. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A. 1998; 95 (17): 9914-9919.
74. Claing A, Laporte SA, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol. 2002; 66 (2): 61-79.
75. Gintzler AR, Chakrabarti S. Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci. 2006; 79 (8): 717-722.
76. Wang L, Gintzler AR. Morphine tolerance and physical dependence: reversal of opioid inhibition to enhancement of cyclic & formation. J Neurochem. 1995; 64 (3): 1102-1106.
77. Wang L, Gintzler AR. Alteredmu-opiate receptor-G protein signal transduction following chronic morphine exposure. J Neurochem. 1997; 68 (1): 248-254.
78. Basheer R, Tempel A. Morphine-induced reciprocal alterations in G alpha s and opioid peptide mRNA levels in discrete brain regions. J Neurosci Res. 1993; 36 (5): 551-557.
79. Parolaro D, Rubino T, Gori E, et al. In situ hybridization reveals specific increases in G alpha s and G alpha o mRNA in discrete brain regions of morphine-tolerant rats. Eur J Pharmacol. 1993; 244 (3): 211-222.
80. Rubino T, Parenti M, Patrini G, Massi P, Parolaro D. Morphine withdrawal syndrome and G protein expression: a study of the time course in the rat central nervous system. Eur J Neurosci. 1995; 7 (11): 2334-2340.
81. Chakrabarti S, Regec A, Gintzler AR. Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure. Brain Res Mol Brain Res. Apr 27 2005; 135 (1-2): 217-224.
82. Chakrabarti S, Rivera M, Yan SZ, Tang WJ, Gintzler AR. Chronic morphine augments G (beta) (gamma) /Gs (alpha) stimulation of adenylyl cyclase: relevance to opioid tolerance. Mol Pharmacol. 1998; 54 (4): 655-662.
83. Chakrabarti S, Wang L, Tang WJ, Gintzler AR. Chronic morphine augments adenylyl cyclase phosphorylation: relevance to altered signaling during tolerance/dependence. Mol Pharmacol. 1998; 54 (6): 949-953.
84. Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006; 79 (18): 1681-1691.
85. Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain. Jun 1995; 61 (3): 365-374.
86. Li Y, Roerig SC. Alteration of spinal protein kinase C expression and kinetics in morphine, but not clonidine, tolerance. Biochem Pharmacol. 1999; 58 (3): 493-501.
87. Narita M, Makimura M, Feng Y, Hoskins B, Ho IK. Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res. 1994; 650 (1): 175-179.
88. Bilsky EJ, Inturrisi CE, Sadee W, Hruby VJ, Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain. 1996; 68 (2-3): 229-237.
89. Yukhananov RY, Kissin I. Comment on Zeitz, K. P., et al., Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC mutant mice, PAIN 94 (2002) 245-253. Pain. Apr 2003; 102 (3): 309-310; author reply 310-301.
90. Zeitz KP, Malmberg AB, Gilbert H, Basbaum AI. Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gammamutant mice. Pain. 2001; 94 (3): 245-253.
91. Liang D, Li X, Clark JD. Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure. Neuroscience. 2004; 123 (3): 769-775.
92. Lou L, Zhou T, Wang P, Pei G. Modulation of Ca2+/calmodulindependent protein kinase II activity by acute and chronic morphine administration in rat hippocampus: differential regulation of alpha and beta isoforms. Mol Pharmacol. 1999; 55 (3): 557-563.
93. Wang ZJ, Tang L, Xin L. Reversal of morphine antinociceptive tolerance by acute spinal inhibition of Ca (2+) /calmodulindependent protein kinase II. Eur J Pharmacol. 2003; 465 (1-2): 199-200.
94. Koch T, Kroslak T, Mayer P, Raulf E, Hollt V. Site mutation in the rat mu-opioid receptor demonstrates the involvement of calcium/calmodulin-dependent protein kinase II in agonistmediated desensitization. J Neurochem. 1997; 69 (4): 1767-1770.
95. Bhargava HN, Cao YJ, Zhao GM. Effect of 7-nitroindazole on tolerance to morphine, U-50, 488H and [D-Pen2, D-Pen5] enkephalin in mice. Peptides. 1997; 18 (6): 797-800.
96. Kolesnikov YA, Pan YX, Babey AM, Jain S, Wilson R, Pasternak GW. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Proc Natl Acad Sci U S A. 1997; 94 (15): 8220-8225.
97. Liang D, Li X, Lighthall G, Clark JD. Hemeoxygenase type 2modulates behavioral and molecular changes during chronic exposure to morphine. Neuroscience. 2003; 121 (4): 999-1005.
98. Liang DY, Clark JD. Modulation of the NO/CO-cGMP signaling cascade during chronic morphine exposure in mice. Neurosci Lett. 2004; 365 (1): 73-77.
99. Minneman KP, Iversen IL. Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature. 1976; 262 (5566): 313-314.
100. Racagni G, Zsilla G, Guidotti A, Costa E. Accumulation of cGMP in striatum of rats injected with narcotic analgesics: antagonism by naltrexone. J Pharm Pharmacol. 1976; 28 (3): 258-260.
101. Lim G, Wang S, Lim JA, Mao J. Activity of adenylyl cyclase and protein kinase A contributes to morphine-induced spinal apoptosis. Neurosci Lett. 2005; 389 (2): 104-108.
102. Smith FL, Javed RR, Elzey MJ, Dewey WL. The expression of a high level of morphine antinociceptive tolerance in mice involves both PKC and PKA. Brain Res. 2003; 985 (1): 78-88.
103. Smith FL, Javed RR, Smith PA, Dewey WL, Gabra BH. PKC and PKA inhibitors reinstate morphine-induced behaviors in morphine tolerant mice. Pharmacol Res. 2006; 54 (6): 474-480.
104. Wagner EJ, Ronnekleiv OK, Kelly MJ. Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling. J Pharmacol Exp Ther. 1998; 285 (3): 1266-1273.
105. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonistMK-801. Science. 1991; 251 (4989): 85-87.
106. Gutstein HB, Trujillo KA. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 1993; 626 (1-2): 332-334.
107. Kest B, Mogil JS, Shamgar BE, Kao B, Liebeskind JC, Marek P. The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc. 1993; 36: 307-310.
108. Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J Neurosci. 1996; 16 (1): 274-282.
109. Zhu H, Jang CG, Ma T, Oh S, Rockhold RW, Ho IK. Region specific expression of NMDA receptor NR1 subunit mRNA in hypothalamus and pons following chronic morphine treatment. Eur J Pharmacol. 1999; 365 (1): 47-54.
110. Manning BH, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996; 67 (1): 79-88.
111. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci. 2001; 933: 175-184.
112. Price DD, Mayer DJ, Mao J, Caruso FS. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage. 2000; 19 (1 Suppl): S7-S11.
113. Lim G, Wang S, Zeng Q, Sung B, Yang L, Mao J. Expression of spinal NMDA receptor and PKC gamma after chronic morphine is regulated by spinal glucocorticoid receptor. J Neurosci. 2005; 25 (48): 11145-11154.
114. Ramkumar V, El-Fakahany EE. Increase in [3H]nitrendipine binding sites in the brain inmorphine-tolerant mice. Eur J Pharmacol. 1984; 102 (2): 371-372.
115. Suematsu M, Ohnishi T, Shinno E, et al. Effect of prolonged administration of clonidine on [3H]PN 200-110 and [125I]omega-conotoxin binding in mouse brain. Neurosci Lett. 1993; 163 (2): 193-196.
116. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain. 2000; 84 (2-3): 271-281.
117. Yokoyama K, Kurihara T, Saegusa H, Zong S, Makita K, Tanabe T. Blocking the R-type (Cav2. 3) Ca2+ channel enhanced morphine analgesia and reduced morphine tolerance. Eur J Neurosci. 2004; 20 (12): 3516-3519.
118. Dogrul A, Bilsky EJ, Ossipov MH, Lai J, Porreca F. Spinal Ltype calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Anesth Analg. 2005; 101 (6): 1730-1735.
119. Smith FL, Dombrowski DS, Dewey WL. Involvement of intracellular calcium in morphine tolerance inmice. Pharmacol Biochem Behav. 1999; 62 (2): 381-388.
120. Matus-Leibovitch N, Vogel Z, Ezra-Macabee V, Etkin S, Nevo I, Attali B. Chronic morphine administration enhances the expression of Kv1. 5 and Kv1. 6 voltage-gated K+ channels in rat spinal cord. Brain Res Mol Brain Res. 1996; 40 (2): 261-270.
121. Campbell VC, Dewey WL, Welch SP. Comparison of [(3) H] Glyburide binding with opiate analgesia, tolerance, and dependence in ICR and Swiss-Webster mice. J Pharmacol Exp Ther. 2000; 295 (3): 1112-1119.
122. Chiou LC, Yeh GC, Fan SH, How CH, Chuang KC, Tao PL. Prenatalmorphine exposure decreases analgesia but notK+channel activation. Neuro Report. 2003; 14 (2): 239-242.
123. Chen X, Marrero HG, Murphy R, Lin YJ, Freedman JE. Altered gating of opiate receptor-modulated K+ channels on amygdala neurons of morphine-dependent rats. Proc Natl Acad Sci U S A. 2000; 97 (26): 14692-14696.
124. Crain SM, Shen KF, Chalazonitis A. Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures. Brain Res. 1988; 455 (1): 99-109.
125. Shen KF, Crain SM. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 1989; 491 (2): 227-242.
126. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007; 21 (2): 131-146.
127. Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ, Chen PX. Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res. 2006; 1069 (1): 235-243.
128. Tai YH, Wang YH, Wang JJ, Tao PL, Tung CS, Wong CS. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. Pain. 2006; 124 (1-2): 77-86.
129. Johnston IN, Milligan ED, Wieseler-Frank J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004; 24 (33): 7353-7365.
130. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci. 2002; 22 (22): 9980-9989.
131. Song P, Liu XY, Zhao ZQ. Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol Sin. 2002; 23 (11): 981-984.
132. Dougherty PM, Harper C, Dafny N. The effect of alphainterferon, cyclosporine A, and radiation-induced immune suppression on morphine-induced hypothermia and tolerance. Life Sci. 1986; 39 (23): 2191-2197.
133. Raghavendra V, Tanga FY, DeLeo JA. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology. 2004; 29 (2): 327-334.
134. Kest B, Hopkins E, Palmese CA, Adler M, Mogil JS. Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav. 2002; 73 (4): 821-828.
135. Liang DY, Guo T, Liao G, Kingery WS, Peltz G, Clark JD. Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. Pain. 2006; 121 (3): 232-240.
136. Liang DY, Liao G, Wang J, et al. A genetic analysis of opioidinduced hyperalgesia in mice. Anesthesiology. 2006; 104 (5): 1054-1062.
137. Liang DY, Shi X, Li X, Li J, Clark JD. The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res. 2007; 181 (1): 118-126.
138. Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioidinduced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics. 2006; 16 (11): 825-835.
139. King M, Su W, Chang A, Zuckerman A, Pasternak GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci. 2001; 4 (3): 268-274.
140. Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol. 2004; 61 (1): 126-148.
141. Dunbar SA, Karamian IG. Periodic abstinence enhances nociception without significantly altering the antinociceptive efficacy of spinal morphine in the rat. Neurosci Lett. 2003; 344 (3): 145-148.
142. Dunbar SA, Karamian I, Zhang J. Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat. Eur J Pain. 2007; 11 (1): 1-6.
143. Rossbach M. Ueber die Gewoehnung an Gifte. Pflugers Archieve Gesamte Physiologie des Menschen. 1880; 21: 213-225.
144. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001; 93 (2): 155-163.
145. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage. 1994; 9 (7): 462-473.
146. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioidmaintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001; 63 (2): 139-146.
147. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage. 2000; 20 (4): 237-245.
148. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001; 90 (1-2): 91-96.
149. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of thosewho do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999; 65 (6): 685-694.
150. Schall U, Katta T, Pries E, Kloppel A, Gastpar M. Pain perception of intravenous heroin users on maintenance therapy with levomethadone. Pharmacopsychiatry. 1996; 29 (5): 176-179.
151. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicininduced hyperalgesia. Anesth Analg. 2003; 97 (3): 810-815.
152. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of themu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106 (1-2): 49-57.
153. Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend. 2006; 82 (3): 218-223.
154. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985; 142 (11): 1259-1264.
155. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997; 4 (5): 231-244.
156. Beck TA, Wright DF, Newman FC, Liese SB. Cognitive Therapy of Substance Abuse. New York, NY: The Guilford Press; 1993.
157. Martin WR, Jasinski DR, Haertzen CA, et al. Methadone-a reevaluation. Arch Gen Psychiatry. 1973; 28 (2): 286-295.
158. Rainville P, Feine JS, Bushnell MC, Duncan GH. Apsychophysical comparison of sensory and affective responses to four modalities of experimental pain. Somatosens Mot Res. 1992; 9 (4): 265-277.
159. Hay JL, White JM, Somogyi AA, Bochner F, Rounsefell B, Semple T. Clinical evidence for opioid-induced hyperalgesia. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 2003; 10: 4.
160. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005; 103 (1): 147-155.
161. Lee LH, Irwin MG, Lui SK. Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. Anesthesiology. 2005; 102 (2): 398-402.
162. Hansen EG, Duedahl TH, Romsing J, Hilsted KL, Dahl JB. Intraoperative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery. Acta Anaesthesiol Scand. 2005; 49 (10): 1464-1470.
163. Troster A, Sittl R, Singler B, Schmelz M, Schuttler J, Koppert W. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology. 2006; 105 (5): 1016-1023.
164. Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S (+)-ketamine, and lidocaine. Anesthesiology. 2001; 95 (2): 395-402.
165. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003; 99 (1): 152-159.
166. Luginbuhl M, Gerber A, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Curatolo M. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg. 2003; 96 (3): 726-732.
167. Compton P, Miotto K, Elashoff D. Precipitated opioidwithdrawal across acute physical dependence induction methods. Pharmacol Biochem Behav. 2004; 77 (2): 263-268.
168. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain. 2003; 4 (9): 511-519.
169. Aley KO, Green PG, Levine JD. Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. J Neurosci. 1995; 15 (12): 8031-8038.
170. Aley KO, Levine JD. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. J Neurosci. 1997; 17 (20): 8018-8023.
171. Aley KO, Levine JD. Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. J Neurosci. 1997; 17 (10): 3907-3912.
172. Aley KO, Levine JD. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. J Neurosci. 1997; 17 (2): 735-744.
173. Arts KS, Holmes BB, Fujimoto JM. Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala2-Gly-NMePhe4-Gly-ol5 (DAMGO) and morphineinduced antinociception in mice. J Pharmacol Exp Ther. 1991; 256 (3): 890-896.
174. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994; 14 (4): 2301-2312.
175. Dunbar SA, Pulai IJ. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. J Pharmacol Exp Ther. 1998; 284 (2): 678-686.
176. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001; 21 (11): 4074-4080.
177. Celerier E, Laulin J, Larcher A, LeMoal M, Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999; 847 (1): 18-25.
178. Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 1999; 89: 631-636.
179. Laulin JP, Larcher A, Celerier E, Le Moal M, Simonnet G. Longlasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 1998; 10 (2): 782-785.
180. Rivat C, Laulin JP, Corcuff JB, Celerier E, Pain L, Simonnet G. Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine. Anesthesiology. 2002; 96 (2): 381-391.
181. Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002; 94 (5): 1263-1269.
182. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000; 92 (2): 465-472.
183. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res. Mol. Brain Res. 2001; 86: 56-62.
184. Celerier E, Simonnet G, Maldonado R. Prevention of fentanylinduced delayedpronociceptive effects in mice lacking theprotein kinase C gamma gene. Neuropharmacology. 2004; 46 (2): 264-272.
185. Sweitzer SM, Wong SM, Tjolsen A, Allen CP, Mochly-Rosen D, Kendig JJ. Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C epsilon and gamma. Pain. 2004; 110 (1-2): 281-289.
186. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000; 20 (18): 7074-7079.
187. Dunbar SA, Karamov IG, Buerkle H. The effect of spinal ibuprofen on opioid withdrawal in the rat. Anesth Analg. 2000; 91 (2): 417-422.
188. Vera-Portocarrero LP, Zhang ET, King T, et al. Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain. 2007; 129 (1-2): 35-45.
189. Li X, Clark JD. Hyperalgesia during opioid abstinence: mediation by glutamate and substance p. Anesth Analg. 2002; 95 (4): 979-984.
190. Belanger S, Ma W, Chabot JG, Quirion R. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 2002; 115 (2): 441-453.
191. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications inmorphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22 (18): 8312-8323.
192. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP, Jr., Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001; 21 (1): 279-286.
193. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 2005; 25 (2): 409-416.
194. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995; 96 (4): 1698-1705.
195. Hemstapat K, Monteith GR, Smith D, Smith MT. Morphine-3-glucuronide’s neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg. 2003; 97 (2): 494-505, table of contents.
196. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000; 27 (7): 524-528.
197. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: amore potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001; 69 (4): 409-420.
198. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993; 55 (1): 93-97.
199. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphineinduced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994; 59 (2): 313-316.
200. Wilson GR, Reisfield GM. Morphine hyperalgesia: a case report. Am J Hosp Palliat Care. 2003; 20 (6): 459-461.
201. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991; 47 (3): 337-339.
202. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain. 1997; 72: 79-85.
203. Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand. 1998; 42 (9): 1070-1075.
204. Heger S, Maier C, Otter K, Helwig U, Suttorp M. Morphine induced allodynia in a child with brain tumour. Bmj. 1999; 319 (7210): 627-629.
205. Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res. 1981; 209 (2): 491-495.
206. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther. 1988; 244 (2): 501-507.
207. Yaksh TL, Harty GJ, Onofrio BM. High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology. 1986; 64 (5): 590-597.
208. Sakurada T, Watanabe C, Okuda K, et al. Intrathecal highdose morphine induces spinally-mediated behavioral responses through NMDA receptors. Brain Res Mol Brain Res. 2002; 98 (1-2): 111-118.
209. Hara N, Minami T, Okuda-Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol. 1997; 121 (3): 401-408.
210. Lawlor P, Walker P, Bruera E, Mitchell S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage. 1997; 13 (6): 356-361.
211. Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth Analg. 2004; 98 (3): 653-659, table of contents.
212. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006; 97 (6): 1611-1626.
213. Goebel DJ, Poosch MS. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2Dand NR3A. Brain Res Mol Brain Res. 1999; 69 (2): 164-170.
214. Zukin RS, Bennett MV. Alternatively spliced isoforms of the NMDARI receptor subunit. Trends Neurosci. 1995; 18 (7): 306-313.
215. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alcohol Rev. 1996; 15 (2): 145-155.
216. Reich DL, Silvay G. Ketamine: an update on the first twentyfive years of clinical experience. Can J Anaesth. 1989; 36 (2): 186-197.
217. Annetta MG, Iemma D, Garisto C, Tafani C, Proietti R. Ketamine: new indications for an old drug. Curr Drug Targets. 2005; 6 (7): 789-794.
218. Sloan TB. Anesthetics and the brain. Anesthesiol Clin North America. 2002; 20 (2): 265-292.
219. Elia N, Tramer MR. Ketamine and postoperative pain-a quantitative systematic review of randomised trials. Pain. 2005; 113 (1-2): 61-70.
220. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev. 2006 (1): CD004603.
221. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg. 2004; 99 (2): 482-495, table of contents.
222. Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand. 1997; 41 (9): 1124-1132.
223. De Kock M, Lavand’homme P, Waterloos H. ‘Balanced analgesia’ in the perioperative period: is there a place for ketamine? Pain. 2001; 92 (3): 373-380.
224. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003; 26 (3): 867-875.
225. Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003; 96 (3): 789-795, table of contents.
226. Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain. 1999; 83 (1): 101-103.
227. Eilers H, Philip LA, Bickler PE, McKay WR, Schumacher MA. The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine. Anesth Analg. 2001; 93 (1): 213-214.
228. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005; 22 (4): 291-294.
229. Axelrod DJ, Reville B. Using methadone to treat opioid-induced hyperalgesia and refractory pain. J Opioid Manag. 2007; 3 (2): 113-114.
230. Chung KS, Carson S, Glassman D, Vadivelu N. Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia. Conn Med. 2004; 68 (9): 547-549.
231. Zimmermann C, Seccareccia D, Booth CM, Cottrell W. Rotation to methadone after opioid dose escalation: how should individualization of dosing occur? J Pain Palliat Care Pharmacother. 2005; 19 (2): 25-31.
232. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003; 26 (2): 769-775.
233. Bowsher D. Paradoxical pain. BMJ. 1993; 306 (6876): 473-474.
234. Skarke C, Geisslinger G, Lotsch J. Is morphine-3-glucuronide of therapeutic relevance? Pain. 2005; 116 (3): 177-180.
235. Katz NP. MorphiDex (MS: DM) double-blind, multiple-dose studies in chronic pain patients. J Pain Symptom Manage. 2000; 19 (1 Suppl): S37-S41.
236. Caruso FS. MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain. J Pain Symptom Manage. 2000; 19 (1 Suppl): S31-S36.
237. Chevlen E. Morphine with dextromethorphan: conversion from other opioid analgesics. J Pain Symptom Manage. 2000; 19 (1 Suppl): S42-S49.
238. Singler B, Troster A, Manering N, Schuttler J, Koppert W. Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth Analg. 2007; 104 (6): 1397-1403, table of contents.
239. Wang QY, Cao JL, Zeng YM, Dai TJ. GABAA receptor partially mediated propofol-induced hyperalgesia at superspinal level and analgesia at spinal cord level in rats. Acta Pharmacol Sin. 2004; 25 (12): 1619-1625.
240. Baba H, Kohno T, Moore KA, Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci. 2001; 21 (5): 1750-1756.
241. O’Rielly DD, Loomis CW. Increased expression of cyclooxygenase and nitric oxide isoforms, and exaggerated sensitivity to prostaglandin E2, in the rat lumbar spinal cord 3 days after L5-L6 spinal nerve ligation. Anesthesiology. 2006; 104 (2): 328-337.
242. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992; 257 (5074): 1276-1279.
243. Yaksh TL, Malmberg AB. Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products. Agents Actions Suppl. 1993; 41: 89-100.
244. Powell KJ, Hosokawa A, Bell A, et al. Comparative effects of cyclooxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance. Br J Pharmacol. 1999; 127 (3): 631-644.
245. Wong CS, Hsu MM, Chou R, Chou YY, Tung CS. Intrathecal cyclooxygenase inhibitor administration attenuatesmorphine antinociceptive tolerance in rats. Br J Anaesth. 2000; 85 (5): 747-751.
246. Quartilho A, Mata HP, Ibrahim MM, et al. Production of paradoxical sensory hypersensitivity by alpha 2-adrenoreceptor agonists. Anesthesiology. 2004; 100 (6): 1538-1544.
247. Davies MF, Haimor F, Lighthall G, Clark JD. Dexmedetomidine fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg. 2003; 96 (1): 195-200, table of contents.
248. De Kock M, Lavand’homme P, Waterloos H. The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery. Anesth Analg. 2005; 101 (2): 566-572, table of contents.
249. Dumont H, Guntz E, Sosnowski M, Talla G, Roman A, Segers B. Opioid-induced hyperalgesia. Eur J Anaesthesiol. 2007; 24 (2): 205-207.
250. Pavlin DJ, Chen C, Penaloza DA, Polissar NL, Buckley FP. Pain as a factor complicating recovery and discharge after ambulatory surgery. Anesth Analg. 2002; 95 (3): 627-634, table of contents.
251. Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d’Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation aftermajor knee surgery. Anesthesiology. 1999; 91 (1): 8-15.
252. Shea RA, Brooks JA, Dayhoff NE, Keck J. Pain intensity and postoperative pulmonary complications among the elderly after abdominal surgery. Heart Lung. 2002; 31 (6): 440-449.
253. Tsui SL, Law S, Fok M, et al. Postoperative analgesia reduces mortality and morbidity after esophagectomy. Am J Surg. 1997; 173 (6): 472-478.
254. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006; 367 (9522): 1618-1625.
255. Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology. 1984; 61: 276-310.
256. de Leon-Casasola OA, Lema MJ. Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivacaine/morphine. Anesthesiology. 1994; 80 (2): 303-309.
257. de Leon-Casasola OA. Postoperative pain management in opioidtolerant patients. Reg. Anesth. 1996; 21: 114-116.
258. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg. 2005; 101 (5 Suppl): S5-S22.
259. Turan A, White PF, Karamanlioglu B, et al. Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. Anesth Analg. 2006; 102 (1): 175-181.
260. Gilron I, Orr E, Tu D, O’Neill JP, Zamora JE, Bell AC. A placebocontrolled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evokedpain after abdominalhysterectomy. Pain. 2005; 113 (1-2): 191-200.
261. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol. 2003; 3 (1): 1.
262. McCrory CR, Lindahl SG. Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg. 2002; 95 (1): 169-176.
263. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth. 2002; 88 (2): 199-214.
264. Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand. 2004; 48 (5): 525-546.
265. Romsing J, Moiniche S, Mathiesen O, Dahl JB. Reduction of opioid-related adverse events using opioid-sparing analgesiawith COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand. 2005; 49 (2): 133-142.
266. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: metaanalysis of randomized controlled trials. Br J Anaesth. 2005; 94 (4): 505-513.
267. Reicin A, Brown J, Jove M, et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop. 2001; 30 (1): 40-48.
268. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg. 2000; 91 (5): 1221-1225.
269. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth. Feb 2003; 90 (2): 166-172.
270. Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth. 2003; 90 (6): 746-749.
271. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther. 2001; 23 (9): 1422-1428.
272. Stoltz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 2002; 97 (1): 65-71.
273. Cheng HF, Harris RC. Renal effects of non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005; 11 (14): 1795-1804.
274. Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adultswith normal renal function. Cochrane Database Syst Rev. 2007 (2): CD002765.
275. Moiniche S, Romsing J, Dahl JB, Tramer MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Analg. 2003; 96 (1): 68-77, table of contents.
276. Hegi TR, Bombeli T, Seifert B, et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br J Anaesth. 2004; 92 (4): 523-531.
277. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332 (7553): 1302-1308.
278. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365 (9458): 475-481.
279. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352 (11): 1081-1091.
280. Nussmeier NA, Whelton AA, Brown MT, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006; 104 (3): 518-526.
281. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005; 28 (3): 227-240.
282. Haller G, Waeber JL, Infante NK, Clergue F. Ketamine combined with morphine for the management of pain in an opioid addict. Anesthesiology. 2002; 96 (5): 1265-1266.
283. Sveticic G, Gentilini A, Eichenberger U, Luginbuhl M, Curatolo M. Combinations of morphine with ketamine for patientcontrolled analgesia: a new optimization method. Anesthesiology. 2003; 98 (5): 1195-1205.
284. Sveticic G, Eichenberger U, Curatolo M. Safety of mixture of morphine with ketamine for postoperative patient-controlled analgesia: an audit with 1026 patients. Acta Anaesthesiol Scand. 2005; 49 (6): 870-875.
285. Duedahl TH, Romsing J, Moiniche S, Dahl JB. A qualitative systematic review of peri-operative dextromethorphan in postoperative pain. Acta Anaesthesiol Scand. 2006; 50 (1): 1-13.
286. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996; 271 (10): 5768-5776.
287. Seib RK, Paul JE. Preoperative gabapentin for postoperative analgesia: a meta-analysis. Can J Anaesth. 2006; 53 (5): 461-469.
288. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain-a systematic review of randomized controlled trials. Pain. 2006; 126 (1-3): 91-101.
289. Fassoulaki A, Stamatakis E, Petropoulos G, Siafaka I, Hassiakos D, Sarantopoulos C. Gabapentin attenuates late but not acute pain after abdominal hysterectomy. Eur J Anaesthesiol. 2006; 23 (2): 136-141.
290. Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg. 2007; 104 (6): 1545-1556, table of contents.
291. LeBlanc KA, Bellanger D, Rhynes VK, Hausmann M. Evaluation of continuous infusion of 0. 5% bupivacaine by elastomericpump for postoperative pain management after open inguinal hernia repair. J Am Coll Surg. 2005; 200 (2): 198-202.
292. White PF, Rawal S, Latham P, et al. Use of a continuous local anesthetic infusion for pain management after median sternotomy. Anesthesiology. 2003; 99 (4): 918-923.
293. Bianconi M, Ferraro L, Ricci R, et al. The pharmacokinetics and efficacy of ropivacaine continuous wound instillation after spine fusion surgery. Anesth Analg. 2004; 98 (1): 166-172, table of contents.
294. Wu CL, Partin AW, Rowlingson AJ, Kalish MA, Walsh PC, Fleisher LA. Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy. Urology. 2005; 66 (2): 366-370.
295. Goldstein A, Grimault P, Henique A, Keller M, Fortin A, Darai E. Preventing postoperative pain by local anesthetic instillation after laparoscopic gynecologic surgery: a placebo-controlled comparison of bupivacaine and ropivacaine. Anesth Analg. 2000; 91 (2): 403-407.
296. Ng A, Swami A, Smith G, Davidson AC, Emembolu J. The analgesic effects of intraperitoneal and incisional bupivacaine with epinephrine after total abdominal hysterectomy. Anesth Analg. 2002; 95 (1): 158-162, table of contents.
297. Kalso E, Tramer MR, Carroll D, McQuay HJ, Moore RA. Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Pain. 1997; 71 (2): 127-134.
298. Moiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A systematic review of intra-articular local anesthesia for postoperative pain relief after arthroscopic knee surgery. Reg Anesth Pain Med. 1999; 24 (5): 430-437.
299. Andersen LJ, Poulsen T, Krogh B, Nielsen T. Postoperative analgesia in total hip arthroplasty: a randomized double-blinded, placebo-controlled study on peroperative and postoperative ropivacaine, ketorolac, and adrenaline wound infiltration. Acta Orthop. 2007; 78 (2): 187-192.
300. Andersen KV, Pfeiffer-Jensen M, Haraldsted V, Soballe K. Reduced hospital stay and narcotic consumption, and improved mobilization with local and intraarticular infiltration after hip arthroplasty: a randomized clinical trial of an intraarticular technique versus epidural infusion in 80 patients. Acta Orthop. 2007; 78 (2): 180-186.
301. Borgeat A, Schappi B, Biasca N, Gerber C. Patient-controlled analgesia after major shoulder surgery: patient-controlled interscalene analgesia versus patient-controlled analgesia. Anesthesiology. Dec 1997; 87 (6): 1343-1347.
302. Lehtipalo S, Koskinen LO, Johansson G, Kolmodin J, Biber B. Continuous interscalene brachial plexus block for postoperative analgesia following shoulder surgery. Acta Anaesthesiol Scand. 1999; 43 (3): 258-264.
303. Singelyn FJ, Ferrant T, Malisse MF, Joris D. Effects of intravenous patient-controlled analgesiawithmorphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty. Reg Anesth Pain Med. 2005; 30 (5): 452-457.
304. de Leon-Casasola OA, Lema MJ. Epidural sufentanil for acute pain control in a patient with extreme opioid dependency. Anesthesiology. 1992; 76 (5): 853-856.
305. Niemi G, Breivik H. The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery. A randomized, double-blind, dose-finding study. Acta Anaesthesiol Scand. 2003; 47 (4): 439-450.
306. Tonner PH. Balanced anaesthesia today. Best Pract Res Clin Anaesthesiol. 2005; 19 (3): 475-484.
307. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2004; 100 (6): 1573-1581.
308. Ackerman WE, 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J Ky Med Assoc. 2006; 104 (9): 419-423.
309. Reuben SS. Preventing the development of complex regional pain syndrome after surgery. Anesthesiology. 2004; 101 (5): 1215-1224.
310. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. J Bone Joint Surg Am. 2007; 89 (6): 1343-1358.
311. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000; 93 (4): 1123-1133.
312. Reuben SS, Rosenthal EA, Steinberg RB. Surgery on the affected upper extremity of patients with a history of complex regional pain syndrome: a retrospective study of 100 patients. J Hand Surg [Am]. 2000; 25 (6): 1147-1151.
313. Parisod E, Siddall PJ, Viney M, McClelland JM, Cousins MJ. Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury. Anesth Analg. 2003; 97 (1): 183-186, table of contents.
314. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol. 1997; 9 (2): 146-148.
315. Guntz E, Talla G, Roman A, Dumont H, Segers B, Sosnowski M. Opioid-induced hyperalgesia. Eur J Anaesthesiol. 2007; 24 (2): 205-207.
316. Ackerman WE, 3rd. Personal communication regarding dosage of IT morphine and associated side effects in case report published in Journal of the Kentucky Medical Association. In: Chu L, ed; 2007.
317. Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage. 2007; 33 (4): 365-371.
318. Orser BA, Bertlik M, Wang LY, MacDonald JF. Inhibition by propofol (2, 6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br J Pharmacol. 1995; 116 (2): 1761-1768.
319. Grasshoff C, Gillessen T. Effects of propofol on N-methyl-Daspartate receptor-mediated calcium increase in cultured rat cerebrocortical neurons. Eur J Anaesthesiol. 2005; 22 (6): 467-470.
320. Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ. Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons. Anesthesiology. 2006; 104 (4): 763-769.
321. Snijdelaar DG, Koren G, Katz J. Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study. Anesthesiology. 2004; 100 (1): 134-141.
322. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage. 2000; 19 (1 Suppl): S21-S25.
323. Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB. CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. J Pain. 2006; 7 (8): 565-574.
324. Bassani F, Bergamaschi M, Tonino Bolzoni P, Villetti G. CHF3381, a novel antinociceptive agent, attenuates capsaicininduced pain in rats. Eur J Pharmacol. 2005; 519 (3): 231-236.
325. Astruc B, Tarral A, Dostert P, Mariotti F, Fabbri L, Imbimbo BP. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. Br J Clin Pharmacol. 2005; 59 (4): 405-414.
326. Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain. 2002; 96 (3): 261-267.
327. Tverskoy M, Oz Y, Isakson A, Finger J, Bradley EL, Jr, Kissin I. Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia. Anesth. Analg. 1994; 78: 205-209.
328. Ilkjaer S, Petersen KL, Brennum J, Wernberg M, Dahl JB. Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Br J Anaesth. 1996; 76 (6): 829-834.
329. Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD. Antihyperalgesic and analgesic properties of the N-methyld-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur J Pain. 2007.
330. Rammes G, Schierloh A. Neramexane (merz pharmaceuticals/forest laboratories). I Drugs. 2006; 9 (2): 128-135.
331. Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, doseescalation study. Clin Ther. 2006; 28 (10): 1607-1618.
332. Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets. 2001; 2 (3): 285-298.
333. Taniguchi K, Shinjo K, Mizutani M, et al. Antinociceptive activity of CP-101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol. 1997; 122 (5): 809-812.
334. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology. 1999; 38 (5): 611-623.
335. Gedeon Richter and Forest Laboratories Expand Relationship with Two New Collaborations for CNS Compounds. http: //www. frx. com/news/PressRelease. aspx?ID=790577. Accessed May 27, 2007.
336. Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med. 2004; 29 (6): 576-591.
337. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003; 19 (5): 286-297.